2025 LCRF Leading Edge Research Grant Program
Riyue Bao, PhD
The University of Pittsburgh
Research Project:
Radiomics to Decipher Patient and Organ Heterogeneity in Response to Immunotherapies in Non-small Cell Lung Cancer
Summary:
Radiomics is emerging as a non-invasive biomarker to predict the efficacy of anti-PD1/PDL1 therapy across cancers as well as which patients with increased organ-level metastasis heterogeneity are more likely to progress. In this study, Dr. Bao’s team aims to develop machine-learning and artificial-intelligence models to distinguish disease control from progression with organ specificity in patients with non-small cell lung cancer. They will further link these findings to tumor biology. Their data will not only shed light on the mechanisms underlying variations in response to immunotherapies but will also provide essential advancement in the non-invasive biomarker development investigating therapy resistance.